Tumor metastasis is the major cause of mortality from cancer. Metabolic rewiring and the
metastatic cascade are highly intertwined, co-operating to promote multiple steps of cancer …

Over the last three decades genetic and biochemical studies have revealed the pleiotropic
effects of the Myc oncoprotein. While cell line studies have defined the intracellular …

Metabolic reprogramming contributes to tumor development and introduces metabolic
liabilities that can be exploited to treat cancer. Chemotherapies targeting metabolism have …

Genetic events in cancer activate signalling pathways that alter cell metabolism. Clinical
evidence has linked cell metabolism with cancer outcomes. Together, these observations …

Adaptation of cellular function with the nutrient environment is essential for survival. Failure
to adapt can lead to cell death and/or disease. Indeed, energy metabolism alterations are a …

The MYC family oncogene is deregulated in> 50% of human cancers, and this deregulation
is frequently associated with poor prognosis and unfavorable patient survival. Myc has a …

The iconic history of the Myc oncoprotein encompasses 3 decades of intense scientific
discovery. There is no question that Myc has been a pioneer, advancing insight into the …

The oncoprotein transcription factor MYC is a major driver of malignancy and a highly
validated but challenging target for the development of anticancer therapies. Novel …

Tumour initiation and progression requires the metabolic reprogramming of cancer cells.
Cancer cells autonomously alter their flux through various metabolic pathways in order to …

Two opposing models have been proposed to describe the function of the MYC oncoprotein
in shaping cellular transcriptomes: one posits that MYC amplifies transcription at all active …